Global Erythropoietin Stimulating Agents Market, By Product Type (Epoetin-Alfa, Epoetin-Beta, Epoetin-Omega, Epoetin-Delta, Darbepoetin-Alfa), Disease Cured (Oncology Diseases, Kidney Disorders, Anemia, Neural Disease, Wound Healing, Antiretroviral Treatment (ART), Cancer Chemotherapy) – Industry Trends and Forecast to 2029.
Erythropoietin Stimulating Agents Market Analysis and Size
The market for erythropoietin stimulating agents is expected to grow in the forecast period of 2022-2029. One of the key factors propelling the market for erythropoietin stimulating agents during the forecast period is the rising frequency of chronic disorders such as CKD and cancer that cause anaemia. Anaemia affects more than 3 million individuals annually, and the national heart, lung, and blood institute of the U.S. department of health and human services predicts that the number will rise throughout the forecast period 2022-2029.
Data Bridge Market Research analyses that the erythropoietin stimulating agents market which was USD 14.46 billion in 2021, would rocket up to USD 31.56 billion by 2029, and is expected to undergo a CAGR of 10.25% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Erythropoietin Stimulating Agents Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Epoetin-Alfa, Epoetin-Beta, Epoetin-Omega, Epoetin-Delta, Darbepoetin-Alfa), Disease Cured (Oncology Diseases, Kidney Disorders, Anemia, Neural Disease, Wound Healing, Antiretroviral Treatment (ART), Cancer Chemotherapy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Amgen Inc (U.S.), Biocon (India), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc (U.S.), Johnson & Johnson Private Limited (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Thermo Fisher Scientific Inc. (U.S.), Hospira Inc. (U.S.), 3SBio Group (China), Celltrion Inc. (South Korea), Intas Pharmaceuticals Ltd. (India)
|
|
Market Opportunities
|
|
Market Definition
The renal tubules produce endogenous erythropoietin (EPO), a glycoprotein hematopoietic hormone. The erythropoiesis mechanism in the bone marrow is controlled and regulated by it. Red blood cell proliferation can be accelerated with the help of erythropoietin stimulating agents (ESAs). For the treatment of anaemia brought on by chemotherapy, HIV, and chronic kidney failure, erythropoietin stimulating drugs are advised. These stimulating substances can also be used to treat low red blood cell counts during complicated surgical procedures.
Erythropoietin Stimulating Agents Market Dynamics
Drivers
- Rising anaemic patients
The market for erythropoietin stimulating agents is expected to develop faster between 2022 and 2029 due to factors such as the rising number of anaemic patients, increasing HIV infections and end-stage renal diseases, rising risk of thrombosis during surgeries, and pure red cell aplasia.
- Rising incidences of disorders impacting the blood cells
Growing prevalence of chronic kidney disease, cancer, HIV, Anemia and several other such disorders is significantly affecting the market and raising the demand for erythropoietin stimulating agents. This is anticipated to lead to the market growth over the next few years.
Opportunities
On the other hand, throughout the forecast period, the availability of biosimilar medications and the uptake of EPO medications in developing countries would present significant prospects for the expansion of the erythropoietin stimulating agents market.
Moreover, an increase in the number of emerging markets and new product launches will further provide beneficial opportunities for the erythropoietin stimulating agents market growth during the forecast period.
Restraints/Challenges
- Stringent Regulatory Guidelines
Stringent regulatory guidelines to obtain product approvals and the adverse side effects of ESAs are expected to hamper the market growth.
- Side effects associated with EPAs
Erythropoietin stimulating agents have been known to exhibit certain side effects in patients taking them as drugs. These might include, fever, swelling, high blood pressure, nausea, dizziness and pain at the injection site. This is estimated to restrict the market growth during the forecast period.
This erythropoietin stimulating agents market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the erythropoietin stimulating agents market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Erythropoietin Stimulating Agents Market
According to a study that was published in the American Journal of Kidney Disease in 2020, ESAs should not be used in the treatment of COVID-19 patients who have anaemia and/or acute kidney injury (AKI), as these patients are unlikely to mount a successful response to ESAs because of the inflammation. Therefore, it is anticipated that the hazards connected with ESA therapy will outweigh any potential benefits. The COVID-19 pandemic is therefore anticipated to impact the researched market's expansion during the pandemic significantly.
Recent Development
- In September 2019, The Darbepoetin Alfa BS Injection JCR, a long-acting erythropoiesis-stimulating agent, was approved in Japan by JCR Pharmaceuticals Co., Ltd. and Kissei Pharmaceutical Co., Ltd. The Phase III trial showed similar safety profiles and equivalency in efficacy and safety when compared to Darbepoetin alpha (innovator product)
- In July 2020, A Phase III clinical trial of Efepoetin Alfa was started by PT Kalbe Genexine Biologics for the treatment of anaemia in people with chronic renal disease who are not receiving dialysis.
- In February 2020, The efficacy of intravenous iron injection, Ferinject, in cancer patients with anaemia was the subject of a multicenter randomised study that Samsung Medical Center started a Phase III clinical trial.
Global Erythropoietin Stimulating Agents Market Scope
The erythropoietin stimulating agents market is segmented on the basis of product type and disease cured. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Epoetin-Alfa
- Epoetin-Beta
- Epoetin-Omega
- Epoetin-Delta
- Darbepoetin-Alfa
Disease Cured
- Oncology Diseases
- Kidney Disorders
- Anemia
- Neural Disease
- Wound Healing
- Antiretroviral Treatment (ART)
- Cancer Chemotherapy
Erythropoietin Stimulating Agents Market Regional Analysis/Insights
The erythropoietin stimulating agents market is analysed and market size insights and trends are provided by country, product type and disease cured as referenced above.
The countries covered in the erythropoietin stimulating agents market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the erythropoietin stimulating agents market due to the rising occurrences of chronic disorders along with the prevalence of various manufacturers in the region.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the rising health awareness among the people and the growing demand of advanced medical technology.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Erythropoietin Stimulating Agents Market Share Analysis
The erythropoietin stimulating agents market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to erythropoietin stimulating agents market.
Some of the major players operating in the erythropoietin stimulating agents market are:
- Amgen Inc (U.S.)
- Biocon (India)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Thermo Fisher Scientific Inc. (U.S.)
- Hospira Inc. (U.S.)
- 3SBio Group (China)
- Celltrion Inc. (South Korea)
- Intas Pharmaceuticals Ltd. (India)
SKU-